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The brain can be considered a complicated system of feedback mechanisms that maintain 
physiological homeostasis. Through psychological activity, neurochemicals act as 
homeostatic regulators. This study proposes that these components are part of a 
regulatory system that is capable of supporting multiple homeostatic regimes that, in turn, 
give rise to self-sustaining psychological behaviors. This project hypothesizes that such 
alternate regulatory programs may play a role in perpetuating psychological dysfunction. 
Interactions within and between components of the neurotransmitter network are 
represented as a set of discrete logic circuits. Neurotransmitter levels are linked to 
psychological constructs such as depression based on current literature. These networks 
were analyzed to find any stable regulatory regimes possible given the established 
connections. Analysis indicated that this model network supported two distinct and stable 
homeostatic regimes. The first corresponds to typical health, while the second presents 
with depression accompanied by increased and decreased levels of various 
neurochemicals. Treatment simulations were then run to mimic the effects of receiving an 
SSRI both in and out of the presence of stress, and to compare recidivism rates of 
returning to a normal regime to real-world statistics. This analysis suggests a new way to 
conceptualize depression as a naturally occurring stable regulatory regime within a 
complex neurotransmitter-psychobehavioral network system capable of supporting 
multiple stable states. Furthermore, it was found that efforts to shift the body’s stable 
regime from depression to health using SSRIs is impeded by stress, suggesting that some 
form of stress management would complement the effects of SSRI treatment.  
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Chapter I: Statement of Problem 
In 2012, an estimated 16 million adults in the U.S. had at least one major 
depressive episode (Substance Abuse and Mental Health Services Administration, 2013). 
This is indicative of several conclusions, such as over the course of a year, 6.9 percent of 
adults in the U.S. experience a period of two weeks or longer during which there is either 
depressed mood or loss of interest or pleasure, and at least four other symptoms that 
reflect a change in functioning, such as problems with sleep, eating, energy, 
concentration, and self-image (American Psychiatric Association, 2013). This also means 
that each year, one of every fourteen adults is at an increased risk of suicide, the tenth 
leading cause of death in the U.S. Apart from the obvious personal ramifications of 
suffering from depression, this disease can have a serious impact on loved ones, 
caregivers, and the economy. In 2010, the annual costs associated with major depressive 
disorder were $210.5 billion. This amount of money is not only staggering, it is also 
rising, compared to the $173.3 billion annual costs associated with the disease in 2005 
(Greenberg et al., 2015). These costs come in many forms, from antidepressant 
medications like SSRIs and psychotherapy treatment hours, to workplace costs like 
increases in annual sick days and higher rates of short-term disability. Depressed workers 
are significantly less productive at work and more likely to be absent. If the cost of 
depression is so high, what is being done to alleviate this crippling issue? There are 
several common forms of treatment available for people suffering from depression 
(Antonuccio, Danton, & DeNelsky, 1995). One of the most common forms is 
psychotropic medication. Selective serotonin reuptake inhibitors (SSRIs) and serotonin 




prescribed to reduce depressive symptoms. More recently, inhibition of GABA transport 
has been investigated in animal models of depression (Salat et al., 2015). Cognitive 
behavioral therapy and interpersonal therapy are among the various types of 
psychotherapies used to treat depression (Cuijpers et al, 2008). Where medications act 
directly on the brain chemistry to alleviate symptoms, psychotherapy acts on mental 
constructs like thought patterns, interpersonal relationships, and coping skills to reduce 
depression. Regardless of the form of treatment, depression has an unusually high 
recurrence rate. Half of all patients who recover from a first episode of depression have 
one or more additional episodes in their lifetime, and nearly 80% of people with a history 
of two episodes will have at least another recurrence. Individuals with a history of 
depression will have five to nine separate episodes in their lifetime (Burcusa & Iacono, 
2007). The numbers alone reveal the serious gravity of this situation. The reason why, 
even treated, depression has a significant recurrence rate, is as shrouded in mystery as a 
key aspect to the disease – the etiology. Despite decades of intensive research, the 
etiology of depression remains elusive. What is clear is that there are biological, genetic, 
environmental, and interpersonal aspects to the cause of major depression. Until it is 
better understood where depression comes from, and what exactly is happening on a 






Chapter II: Review of the Literature 
One of the most primary concerns in understanding and treating depression is to 
first understand what is meant by “depression.” Asking any two people suffering from 
depression to describe in detail the components of their suffering will likely result in very 
different answers. Indeed, the one of the most defining features of psychological 
constructs is their inherent subjectivity. No two people can directly share the same 
subjective experience, and therein lies one of the most fundamental issues when 
understanding a mental state like depression. Not only in subjective experience, but also 
in clinical presentation, depression can mean different things to different people. The 
current version of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) 
contains eight distinct disorders under the “Depressive Disorders” category (American 
Psychiatric Association, 2013). Additionally, many other disorders within the DSM-5 
contain potential specifiers of depressed mood in addition to the disorder. The 
specifically depressive disorders, however, are eight functionally unique presentations of 
depression. The common feature of these disorders is the presence of sad, empty, or 
irritable mood, accompanied by somatic and cognitive changes that significantly affect 
the individual’s capacity to function. What differs among them are issues of duration, 
timing, or presumed etiology. The most common and central depressive disorder, Major 
Depressive Disorder (MDD), is at the core of this category. Beyond the variances that 
exist within this category (duration, timing, etiology, etc.), MDD primarily consists of 
that which can be found in the other depressive disorders, namely, a major depressive 
episode. This central component of the depressive disorders is typically what is being 




of the DSM, professionals within the mental health field have narrowed down the specific 
criteria necessary to adequately describe a major depressive episode. Currently, the 
criteria are as follows:  
A. Five (or more) of the following symptoms have been present during the same 2-
week period and represent a change from previous functioning; at least one of the 
symptoms is either (1) depressed mood or (2) loss of interest or pleasure. 
1. Depressed mood most of the day, nearly every day, as indicated by either 
subjective report (e.g., feels sad, empty, hopeless) or observation made by 
others (e.g., appears tearful). 
2. Markedly diminished interest or pleasure in all, or almost all, activities 
most of the day, nearly every day (as indicated by either subjective 
account or observation). 
3. Significant weight loss when not dieting or weight gain (e.g., a change of 
more than 5% of body weight in a month), or decrease or increase in 
appetite nearly every day. 
4. Insomnia or hypersomnia nearly every day. 
5. Psychomotor agitation or retardation nearly every day (observable by 
others, not merely subjective feelings of restlessness or being slowed 
down). 
6. Fatigue or loss of energy nearly every day. 
7. Feelings of worthlessness or excessive or inappropriate guilt (which may 





8. Diminished ability to think or concentrate, or indecisiveness, nearly every 
day (either by subjective account or as observed by others). 
9. Recurrent thoughts of death (not just fear of dying), recurrent suicidal 
ideation without a specific plan, or a suicide attempt or a specific plan for 
committing suicide. 
B.  The symptoms cause clinically significant distress or impairment in social, 
occupational, or other important areas of functioning. 
C. The episode is not attributable to the physiological effects of a substance or to 
another medical condition.  
What is of particular note when discussing the definition of “depression,” is that 
even within this well defined clinical explanation, only five of the nine criteria are 
required, with one of those five being at least one of the first two criteria. This echoes the 
earlier idea of depression being a fundamentally subjective and difficult to quantify 
phenomenon. While a pinpoint singular definition of depression has remained elusive, the 
cluster of potential clinical symptoms has been mostly sufficient for professionals within 
the various health fields to label, discuss, and develop treatments for depressed patients 
and clients. However, the lack of a clear and distinct mechanistic understanding of 
exactly what is happening in the body and mind of someone suffering from depression 
leads inevitably to the lack of clear and distinct methods of efficient treatment. If, while 
on a walk through the woods, someone is bitten by a venomous spider, they can be 
quickly taken to the nearest hospital or clinic and given specific anti-venom to counteract 
the spider’s damage. This is possible because of the knowledge of the mechanisms 




is afflicted with depression, prescribing an anti-depressant does not always effectively 
treat his or her symptoms. Nor do all anti-depressant medications equally treat all 
patients. This is due to an overwhelmingly unfortunate lack of understanding of the 
mechanisms that underlie this illness. The outward symptoms and expressions of 
depression can be observed, described, and in some cases quantified. Despite debate 
between mental health professionals of these symptoms and expressions, they tend to do 
a more or less sufficient job at describing depression. What they do not do, however, is 
point to a specific etiology, a system of mechanisms, or a clearly defined, individualized 
treatment protocol. 
 The complexity of depression doesn’t stop with the nebulous nature of its 
symptoms and characteristics. Depression rarely occurs in a vacuum. More often than 
not, someone suffering from clinical depression is also suffering from one or more of a 
myriad of other, clinically different diseases or disorders (Kang, et al., 2015; Hasin, et al., 
2018). A study done of patients with a lifetime history of MDD found that 57.9% had a 
history of a substance use disorder, 37.3% had a previous anxiety disorder, and 31.9% 
had a history of a personality disorder. Additionally, they found that 74.6% of MDD 
cases included the anxious/distressed specifier (Hasin, et al., 2018). A 1-year prevalence 
study in the United States found that patients with chronic medical diseases were nearly 
three times more likely to get depressed than their healthy counterparts (Egede, 2007). 
Another study of patients from 60 countries found that 9.3% to 18% of subjects with a 
single physical disorder also suffered from depression, compared to 3.2% of subjects 
without a single physical disorder, and 23% of patients with two or more physical 




on these comorbidities have found a significant level of depression in 20.4% of breast 
cancer patients, 20.7% of stroke patients, and 20.7% of patients with acute coronary 
syndrome (Kang, et al., 2015). Additionally, 33.8% of patients with chronic pain meet 
criteria for severe depression, with 60.8% meeting criteria for probable depression, based 
on specific measures (Rayner, et al., 2016). The comorbidity with chronic pain is 
particularly sinister, as the pain tends to exacerbate the patient’s depression, which, in 
turn, exacerbates the pain perception, creating a vicious cycle. A possible key player in 
all of these comorbidities could be the link between depression and the immune system. 
Recent studies suggest that proinflammatory cytokines may contribute to some of the 
major symptoms of depression (Dowlati, et al., 2010). This connection between 
depression and a compromised immune system creates a new clinical picture, one that 
considers multiple levels of mechanistic action within the patient and may help account 
for many of the other comorbidities already mentioned. Some of these comorbidities 
seem obvious. It is fairly intuitive that someone suffering from chronic pain or going 
through the challenges of a cancer diagnosis would take a subsequent, and sometimes 
significant, hit to their mood functioning. However, whether the connection is obvious or 
more surprising, the implication is that depression and its mechanisms of action are part 
of a much deeper and more complex clinical symptom constellation that may require a 
new way of thinking to adequately understand, and ultimately treat, depression.  
 The concept of modeling depression has a long history. In Ancient Greece, 
Hippocrates theorized that diseases, including “melancholia,” or what we now might call 
depression, could be explained by Imbalances in four basic bodily fluids, or humors 




depression began to be modeled and explained in the context of psychology. In 1917 
Sigmund Freud first developed a psychoanalytic view of depression, or melancholia, 
stating that it can result from an objective loss, such as the loss of a valued relationship, 
leading to subjective loss, the mechanism of which is the depressed individual’s 
identification with the object of affection through an unconscious, narcissistic process, 
which he called the libidinal cathexis of the ego. As the field of psychology developed 
further, new theorists began attempting to understand depression from new points of 
view. In the 1950s, cognitive psychologists began theorizing explanations and models for 
depression. Albert Ellis hypothesized that depression stemmed from irrational “shoulds” 
and “musts” which would lead to inappropriate self-blame, self-pity, and other-pity (Ellis, 
1962). In 1972 Martin Seligman developed the idea that learned helplessness underlies 
depression. In his theory, repeated exposure to aversive stimuli would reinforce a sense 
of regular helplessness in the individual, which would consequently result in depressed 
mood. In the 1960s and 70s, Aaron Beck developed one of the first true interactional 
models of depression (Beck, 1967). In his “cognitive triad,” depression resulted from 
negative thinking patterns about oneself, one’s future, and the world. These negative 
schemas were bidirectional, and influenced one another creating vicious cycles and 
rudimentary feedback loops. Utilizing Beck’s theories, cognitive-behavioral therapy has 
become one of the most successful and widespread forms of treatment for depression in a 
variety of populations (Brown, et al., 2016; Ballesio, et al., 2018; Twomey, et al., 2017; 
Unwin, et al., 2016). The success and efficacy of CBT speaks to the utility of a 
depression model that incorporates interacting components such as Beck’s. 




key players (e.g., cognitions, trauma, beliefs, etc.), medical models of the illness have 
often focused on more concrete ways of conceptualization. These models tend to rely on 
physical components such as chemical imbalances in the brain (Valenstein, 1998), 
degenerative conditions (Wragg & Jeste, 1989), toxicological syndromes (Onishchenko, 
et al., 2008), injuries (Jorge, et al., 2004), or deficiency states (Poeldinger, Calanchini, & 
Schwarz, 1991) to adequately explain the etiology of depression. Mirroring its 
conceptualizations, the medical models of depression offer treatments that often target 
physiological constructs. As opposed to psychological treatments, they rely on the use of 
medications, or antidepressants. The idea that depression is the result of a chemical 
imbalance in the brain took root in the 1950s. New clinical trials testing anti-tuberculosis 
drugs began to show a significant effect on the mood of patients. Specifically, these drugs 
were improving the mood of patients who were also diagnosed with depression (López-
Muñoz & Alamo, 2009). The world of psychopharmacology grew rapidly after this 
discovery, with various types of drugs being developed over the following years to treat 
mood disorders, including depression. Mono-amine-oxidase inhibitors (MAOIs) and 
tricyclic antidepressants (TCAs) were among the first types of widely available 
antidepressants. As mentioned, the nature of depression is complex, however, and it 
quickly became apparent that not all drugs are created equal. Efficacy rates varied among 
classes of drugs and types of depression, and side effects from these drugs could often be 
severe. However, the scientific value of these drugs cannot be understated. They provided 
highly relevant data on the action mechanisms of pharmacological agents at the synaptic 
transmission level. This level of understanding opened the door for new, more specific 




role that serotonin plays in depression, SSRIs have become one of the gold standards for 
pharmacological treatment of depression. It acts by blocking the reabsorption of serotonin 
into the presynaptic cell, increasing the extracellular level of serotonin in the synaptic 
cleft available to bind to the postsynaptic receptor. The use of this medical model of 
depression has allowed researchers to better understand at least part of the mechanisms of 
depression. However, the efficacy rates of all antidepressants, including SSRIs are highly 
debated, but conservative estimates putting the remission rate of SSRIs around 50-60% 
(Linde, et al., 2015). This suggests that current physiological models are far from 
complete. A major hurdle in these biological models of depression is matching the 
complexity of the disease. Serotonin and other neurotransmitters may be key players, but 
until these models can account for all active contributing aspects during a depressive 
episode, treating the disease will continue to stop with covering of symptoms. An apt 
analogy may be that the success rate of a baseball team may be improved by training the 
pitcher, a key player, but unless you understand and train all players on the field, that 
success rate of the team will continue to be severely limited.  
 The current study takes an unconventional approach to a better understanding of 
major depression. In an ongoing effort to create a comprehensive modeling network to 
better understand various complex chronic illnesses, an interactional biobehavioral model 
of imbalances was built using existing literature and drawing connections between 
various neurochemicals and behavioral constructs. The model started as a biobehavioral 
point of entry into existing models of complex illnesses such as Chronic Fatigue 
Syndrome and Gulf War Illness. In an effort to better understand the psychological 




(depression, anxiety, fatigue, hyperarousal, etc.) as well as common neurotransmitters 
often implicated in the activation or reduction of these behavioral constructs (serotonin, 
dopamine, norepinephrine, etc.) were chosen to build the first iteration of our 
interactional biobehavioral model of imbalances. A literature review was then conducted, 
searching for any and all established connections between any two nodes of the model 
(e.g., any clinically established effect that serotonin has on GABA, and vice versa). By 
creating a system of feedback and feed-forward mechanisms and applying to it a ternary 
logic set of interaction rules, complex homeostatic regimes can be found. These regimes 
may give a new level of systematic insight into the underlying physiology of various 
illnesses.  
The problem addressed by this study is the lack of a comprehensive and detailed 
understanding of the physiological mechanisms underlying mental illness. Feedback 
mechanisms throughout the brain play a significant role in maintaining physiological 
homeostasis. Specifically, brain chemicals and neurotransmitters contribute important 
oversight of psychological activity and homeostatic regulation. This paper proposes that 
these components form an overarching regulatory system that is capable of supporting 
multiple homeostatic regimes, including maladaptive illness states. Moreover, these 
regimes give rise to psychological behaviors that emerge as a result of the extensive 
feedback mechanisms involved in neurotransmitter signaling. Indeed, many 
psychological issues such as depression, anxiety, personality disorders, and post-
traumatic stress reactions display a certain element of chronicity, almost as if the person 
suffering is “stuck” in a vicious cycle of distress. Here, this paper models the interaction 




homeostatic regulation. Initial analysis of the model found homeostatic regimes that 
could possibly help garner a more complete understanding of the perpetuation of 
depression and anxiety. In addition, this work simulates an SSRI treatment by altering the 
level of serotonin in the model, comparing the evolution of the model from depression to 
health to known SSRI treatment success rates. Simulations such as these add to the 
validity of the model to accurately represent a naturally occurring physiological state. 
Though coarse, these models may nonetheless support the design of robust new 
treatments. As a further exploration and to cast SSRI treatment in a broader context, the 
introduction of GABA inhibition both alone and in combination with SSRI treatment was 
simulated. In all cases the model found a significant contribution of behavioral stress 
management to improving the predicted rate of remission beyond that achieved by 






Chapter III: Material and Methods 
A Psychobiology Regulatory Model 
An important obstacle in building models across regulatory systems remains the 
scarcity of detailed human in vivo kinetic data as its collection can present significant 
health risks to subjects. The model proposed here circumvented this using a discreet logic 
representation based solely on literature of physiological and biochemical connectivity to 
provide a qualitative description of system behavior. The model addressed only a handful 
of neurochemicals that were chosen based on their prevalence in the literature and their 
perceived importance in various aspects of psychological functioning. While this limited 
set by no means fully accommodates the vast complexity of the neurological signaling 
system underlying psychological function and behavior, the corresponding coarse-
grained circuit model supports a first approximation of physiologically relevant and 
experimentally verifiable response dynamics. The components of the model were chosen 
based on a specific set of criteria, the first of which was the limitations of the modeling 
technology employed. The methodology of analyzing these functional kinetic networks 
require significant computing power based on the number of nodes in the network, as 
well as the total number of incoming connections to each node. Based on these 
constraints, a target of 15-20 nodes was chosen. The final count of 16 nodes included 9 
physiological neurochemicals, 6 psychological constructs, and stress. The psychological 
constructs were chosen based on two criteria: the goal of analyzing depression and 
anxiety as part of a functional feedback network, and readily available laboratory data to 
facilitate further future study of the network and its analyses. These criteria led to the 




fatigue as the psychological construct nodes. Once these nodes were decided on, a brief 
literature review was conducted to determine what neurochemicals were primarily 
involved in the functioning of each psychological construct. This led to the inclusion of 
cortisol, dopamine, serotonin, glutamate, GABA, neuropeptide y, acetylcholine, 
epinephrine, and norepinephrine. Finally, a general node for stress was included to 
analyze how the system might evolve under the influence of a stress response, essentially 
mimicking in a very coarse-grained way, the real life conditions under which a 
neurobehavioral network would find itself. Once the list of neurotransmitters was decided 
upon, a literature review was conducted to discern how each chemical influenced the 
others. Priority was given to data observed in humans. Where there was limited or no 
data directly observed in humans, non-human animal studies were accepted. Furthermore, 
while many of the connections between these neurochemicals can be very complex, and 
differ based on brain region, genetic changes, and other confounding variables, for the 
purpose of this model, a general regulatory dynamic was chosen between any two nodes 
based on the overall, average way that the nodes caused each other to behave, as reported 
in literature. In the following section, each of these signaling connections are described 
with references to the supporting literature.  
 Cortisol is a steroid hormone released in response to stress, and therefore is a key 
element in any psychological homeostatic regime, as stress plays a significant role in 
psychology and the induction of maladaptive psychological states like depression. Based 
on the literature review, it was determined that cortisol is necessary for the activity of the 
synthesizing enzyme responsible for epinephrine (Wurtman, et al., 1972). Furthermore, 




glucocorticoids contribute to an increase in dopaminergic activity (Piazza, et al., 1996). 
They also increase glutamatergic transmission in the prefrontal cortex through modifying 
postsynaptic NMDA and AMPA receptors (Yuen, et al., 2009). Increased cortisol also 
inhibits serotonin levels by increasing serotonin uptake (Tafet, et al., 2001). 
 Various additional connections between the different nodes of the model were 
also found through the literature review. Elevated levels of epinephrine, for example, are 
shown to increase anxiety (Janssen, et al., 1998). Dopamine, applied iontophoretically, 
consistently attenuates the inhibitory actions of GABA (Bergstrom & Walters, 1984). 
Similarly, dopamine acts antagonistically with serotonin (Daw, et al., 2002), neuro 
peptide y (Gillard, et al., 1993), and norepinephrine (El Mansari, et al., 2010). Dopamine 
also has an inverse relationship with acetylcholine (Calabresi, et al., 2006). According to 
current literature, neuropeptide y (NPY) can block the phase shift of glutamate, reducing 
its cortical levels (Biello, et al., 1997). Increases in NPY can also inhibit levels of 
acetylcholine and norepinephrine (Serfozo, et al., 1986), and serotonin (Dryden, et al., 
1993). According to Herman et al. (2003), norepinephrine pathways modulate synthesis 
of GABA in central limbic stress circuits. Elevated levels of norepinephrine also promote 
neuropeptide y (Wahlestedt, et al., 1990). Behaviorally, this neurotransmitter can increase 
anxiety (Bremner, et al., 1996), hyperarousal (Southwick, et al., 1999), attention 
(Bymaster, et al., 2002), and working memory (Zhang, et al, 2004), and decrease 
depression (Delgado & Moreno, 1999).  
 GABA, or gamma-Aminobutyric acid, is a primary inhibitory neurotransmitter. 
Therefore by increasing its levels, dopamine (Casey, et al., 1980), norepinephrine 




2004). Elevated GABA can also lead to decreased levels of attention (Edden, et al., 
2012). As opposed to GABA, glutamate is a primary excitatory neurotransmitter in the 
brain. It acts by increasing levels of norepinephrine (Russell & Wiggins, 2000), cortisol 
(Mathew, et al., 2001), and GABA (Carlsson, et al., 2001), and also increasing working 
memory (Aultman & Moghaddam, 2001) and depression (Paul & Skolnick, 2003). It can, 
however, inhibit attention (Carrey, et al., 2007). 
 Serotonin is one of the primary neurotransmitters involved in depression (van 
Praag, et al., 1987). It is often the target of pharmaceutical interventions for depression. 
Because of the key role serotonin plays in this disorder, its place in the model is of 
particular importance. Based on current literature, elevated serotonin can lead to a 
number of different things. Certain serotonin receptors can facilitate glutamate release 
(Aghajanian & Marek, 1999). Serotonin also depolarizes certain cell types to increase 
acetylcholine release (MacDermot, et al., 1979). Serotonin has also been found to have a 
reciprocal relationship with norepinephrine (Guiard, et al., 2008), dopamine (Korsgaard, 
et al., 1985), cortisol (O’hara, et al., 2007), and GABA (Bankson & Yamamoto, 2004). 
Psychologically, elevated serotonin can increase hyperarousal (Connor & Davidson, 
1998), but inhibit both anxiety (Charney, et al., 1987) and depression (Owens & 
Nemeroff, 1994). One study also found that keeping serotonin levels high for too long 
can lead to serotonin syndrome, with one symptom being physical fatigue (Roelands & 
Meeusen, 2010). 
 Acetylcholine is a neurotransmitter that acts on both the peripheral nervous 
system (PNS) and the central nervous system (CNS). For discussion within this model, its 




epinephrine (Keely & Lincoln, 1978), neuropeptide y (Dixon, et al., 2000), and cortisol 
(Walker, et al., 1990), while decreasing levels of norepinephrine (Kalsner & Quillan, 
1988) and serotonin (Leboulenger, et al., 1988). Behaviorally, increased acetylcholine 
activity can increase hyperarousal (Czermak, et al., 2008), attention (Botly & Rosa, 
2008), and working memory (Daniel & Dohanich, 2001). 
 It is of note that these aforementioned connections represent a “normal model” of 
functioning. There are likely to be deviations from this model at the individual level, but 
these deviations should be apparent by comparing an individual with this “averaged 







Coarse Logic Model of Behavior and Neurotransmission in the Brain and 
Corresponding Behavioral Constructs. A simple causal regulatory network model 





Discrete Ternary Logical Analysis 
The discrete ternary logical network analysis used in the present work is an 
extension of a methodology proposed by Mendoza and Xenarios (2006) and Thomas 
(1991), and has been reported previously in the construction and analysis of similar 
models focused on the HPA axis and components of immune functioning (Craddock et 
al., 2014; Fritsch et al., 2013). This project encodes documented feedback mechanisms 
within the neuro-psychological system using only the direction (source and target) and 
type (activator or inhibitor) of interaction. As data describing the magnitude of changes 
remains limited, all cell types and behavioral constructs are considered to be equally 
responsive to the actions of the neurotransmitters for which they express receptors. 
Accordingly, neurochemical synthesis is also considered to be equivalent regardless of 
source. Using this formalism, the number and type of stable resting states supported by 
the regulatory circuitry as well as the specific qualitative neuro-psychological signatures 
at each of these stable points could be determined without requiring detailed kinetic 
information. That is, the proposed model determines where the system would eventually 
come to rest even though it may not be known how quickly this equilibrium will be 
reached.  In this model, signaling molecules and cell types are represented as individual 
variables each capable of adopting 3 discrete states: -1 (down-regulated), 0 (nominal), 
and 1 (up-regulated). At any point in time t, the state of a system with N variables can be 
represented by the vector , such that: 
      (1) 
where s the state of the ith variable of the N variable system at time t. The image 
vector  describes the preferred state towards which the system evolves in the next 
!x(t)






time increment. The state value of the image vector for the ith variable is determined from 
its current state and a set of balanced ternary logic statements based on the current value 
of variable and the mode of action (i.e. activate or inhibit) of the neighboring input 
variables. These logic statements are expressed as follows (Eq. 2):  
   (2) 
where the Ñ, Ú, and ¬ symbols are ternary HIGH/LOW PASS, OR and NOT operators, 
 is the state of the ith variable’s jth activator, is the state of the ith variable’s kth 
inhibitor. The ternary operators given in Equation (2) are described in further detail in 
Craddock et al. (2014) and Fritsch et al. (2013). The first entry in Equation (2) is used 
when the variable possesses X activators and Y inhibitors, the middle when the variable 
has only X activators and last when the activator has only Y inhibitors.   
 The number of nodes determines the total number of allowable states available to 
a model, such that a model of N nodes possesses 3N states. Steady states are defined as 
those state nodes from which there is no allowable escape or which possesses an out 
degree of 0. Since the current regulatory network model (Figure 1) contains 15 soluble 
mediators and behavioral constructs, the number of possible system states is 315 = 
14,348,907. Though quite large this remains a computationally tractable problem and an 
exhaustive search of all possible state nodes was conducted to determine which of the 
latter constituted a steady homeostatic state as in Fritsch et al., (2013). 
Monte Carlo Simulation of State Evolution  
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applying a Monte Carlo algorithm. From any initial starting state, allowable state 
transitions are determined based on Equation (2). Applying the latter to each variable in 
the model for the mth state of the system, , defines the image vector  for the 
mth state. With  defined, the system is updated asynchronously (allowing only 
one variable to change at a time) following the generalized logical analysis of Thomas 
(1991). According to this method the ith variable of the mth state vector  is moved 
one step towards its preferred image  (e.g. If  = -1 and  = 1, then 
 is set to 0). Thus, for each current state of the system there are potentially 
several subsequent states towards which it may asynchronously evolve. From the 
allowable transitions a target state is chosen at random using a uniform equal distribution 
and used to generate the next set of allowable target states. Executing the simulation 
multiple times gives a distribution of paths that is used to determine the behavior of the 
system from any given start state.  
Simulating Intervention Courses 
To identify a robust sequence of interventions capable of moving the neuro-
psychological system from a pathological mode of regulation to that of normal health, 
solutions combining a specific choice of treatment targets (e.g., serotonin uptake 
inhibition and/or GABA inhibition) as well as the sequence, spacing and type of external 
perturbation were allowed to evolve through the system. For each of these candidate 
treatment courses, simulations were conducted to evaluate the occurrence of normal 
homeostasis. Specifically, each clinical intervention of serotonin and/or GABA 
modulation was represented as a treatment vector with N variables. Interventions applied 













to the system state at some point in time t, were represented by the vector , such that: 
     (4) 
where  is a ternary value describing the effect of the clinical treatment on the ith 
element of the system: -1 (suppressing), 0 (untreated), and 1 (elevating). At those time 
points where an intervention is being applied, the image vector  describing the 
preferred state towards which the system should evolve is now defined as follows in 
contrast to the unperturbed logic described in Eq. 2: 
      (5) 
 Due to the ternary nature of this system no value can extend beyond the range of -
1 to 1, hence values beyond this range were rounded accordingly (i.e. if and 
, then is rounded to 1). At times t when there is no 
treatment applied (i.e. all ), state transition continues according to the logic in Eq. 
2. 
Genetic Algorithm for Optimizing Treatment Course 
Using this model-based strategy, repeated simulations were performed, each with 
a new externally applied intervention as prescribed by a global search algorithm in order 
to identify the optimal selection and spacing of interventions involving serotonin uptake 
inhibition, GABA suppression, or a combination of both leading to stable remission. A 
Genetic Algorithm (GA) based search (Whitley et al., 2003) was used to optimize this 
treatment course, as its form naturally accommodates the discrete definition of each 






















A treatment course vector  with M interventions is therefore defined as, 
    (6) 
where  is the intervention treatment vector at the ith intervention time point. Due to 
the asynchronous nature of the model each treatment vector  only contains a single 
target intervention  that affects the ith element variable in the system at any given time 
step. 
The GA starts by generating a population of 1000 candidate treatment courses 
each composed of a specific number of randomly selected interventions consisting of 
serotonin re-uptake inhibition, GABA inhibition or both, applied at random points along 
the time course. The response of the system to each treatment course in this initial 
generation of candidates is then simulated for 1000 time steps. Over the course of these 
time steps the state of the system evolves according to Eq. 2, except at those times when 
interventions are applied. At these intervention events the state transition follows Eq. 5. 
These 1000 iterations provide a distribution of paths that are then ranked according to a 
fitness function based on the number of times a treatment successfully reached the 
healthy stable state (% HHM). After all treatments in the generation have been ranked, 
the top 10% are retained without change for the next generation. Thus, treatments 
generated by the GA that have a higher probability of leading to the HHM are re-
executed and re-evaluated over many generations. The remainder of the next generation 
of candidate solutions is created by choosing random pairs from the total set of treatment 
courses (including the top 10th percentile) and combining (cross-over recombination) 

























random splice point s to create a new treatment course  for the next generation, such 
that, 
  (7) 
The response to the new treatment courses, including members of the previous top 
10th percentile, are then simulated once again and ranked as a new generation. This 
process is continued iteratively for 1000 generations. The final treatment course with the 
highest % HHM was taken as the best treatment solution for a given run. The overall best 
treatment course was chosen from 100 repeated GA runs. Optimal pharmacological 
interventions identified in this way were repeated, this time with the addition of stress, 
simulated as an increase in cortisol. This stress was added to the treatment vector 
randomly across the time course, such that the stressful events occurred at a prescribed 
frequency (e.g. 30% or one out of every three time points). 
Sensitivity Analysis 
To develop an understanding of a possible predisposition to falling into the 
depressed steady state based on the logic and wiring of the model, a sensitivity analysis 
was conducted. Starting at health, each neurotransmitter, one at a time, was either held 
high or low, and the system was allowed to respond naturally following a stressful event 
serving as a trigger. This was repeated 1000 times for both abnormal levels of each 
neurotransmitter to determine a percentage of times that the system degenerated into the 
depressed attractor, thus demonstrating which neurotransmitters, if any, had the greatest 






































Pathway Analysis  
Once it was established that increased levels of glutamate provided the backdrop 
for the quickest descent into the depressed steady state, the network was run while 
holding glutamate high to find the step-by-step path of the shortest route to illness. While 
there may be many possible routes to illness, this theoretical route would be the shortest, 





Chapter IV: Results 
Multiple Stable Behaviors 
As described above, steady homeostatic states are defined as those states to which 
the system naturally evolves at rest. These were determined here by enumerating all 
possible states that may be occupied by the model shown in Figure 1. This exhaustive 
search pointed to two steady homeostatic states (SS) where neurotransmitter and psycho 
behavioral constructs converged to the levels described in Figure 2. The reference steady 
state (SS0) described typical health with all markers being expressed at their nominal 
levels or zero. In addition to typical healthy regulation (SS0) we found that the model can 
also accommodate a shift towards an exacerbated depressive state with increased anxiety 
accompanied by reduced physical fatigue, impaired attention, and chronically low levels 
of serotonin in the context of elevated cortisol, GABA, and epinephrine. This would 
suggest that persistent depressive mood might be perpetuated at least in part by normal 
regulatory circuitry. 
Simulating Conventional Treatment with SSRI 
A common pharmaceutical treatment for depression focuses on the 
neurotransmitter, serotonin. Specifically, selective serotonin reuptake inhibitors (SSRIs) 
increase the amount of serotonin in the brain by blocking its reuptake into presynaptic 
neurons. This increase in serotonin affects mood, and can decrease depression, consistent 
with the wiring of this model. While reported efficacy rates of SSRIs vary greatly, current 
statistics put the efficacy rate of SSRIs in clinic at around 50-60% (Linde, et al., 2015). 








Multiple Naturally Occurring Stable States. This basic model of neurotransmission 
supports an alternate homeostatic state where physiologic regulation now ensures a 
sustained depressive state with increased anxiety accompanied by reduced physical 
fatigue, impaired attention, and chronically low levels of serotonin in the context of 











simulated computationally. First a numerical optimization was applied to identify the 
frequency of treatment with exogenous serotonin that delivered the highest predicted rate 
of lasting remission. Because the state of model neurotransmission network evolves in a 
probabilistic manner, a second step of simulation involved the artificial introduction of 
available serotonin according to this optimal frequency in 100 repeated treatment rounds, 
each in 100 simulated subjects. This was performed based on a schedule of predicted 
optimal treatment frequencies that encompassed between 2 and 8 treatment cycles.  
To include the effects of stress on neurotransmission patterns in the model, and since real 
world subjects must deal with environmental stressors, random stressful events were 
superimposed at a frequency of occurrence of 30%. Under these simulated real-world 
conditions, the rate of predicted treatment responses potentially leading to lasting 
remission increased with repeated treatment, eventually reaching a saturation level of 
roughly 75% after 8 simulated cycles of SSRI treatment (Figure 3).  
Simulating Combination Therapy with GABA Inhibition 
Treatment with GABA inhibitors is also often used as a second line of therapy. 
Again, the numerical optimization was repeated, this time allowing for the optimal 
scheduling of both SSRI intervention as well as SSRI alone or in combination. The 
optimal treatment course of combination therapy repeated from 2 up to 8 cycles were 
again simulated 100 times each in a 100 virtual subjects. Overall, it was determined that 
these optimal treatment courses only included GABA inhibition very sparingly and that 
the primary driver was SSRI treatment. Nonetheless, the inclusion of GABA blockade 
improved the predicted remission rates slightly under simulated real-world conditions of 






Simulated Intervention Time Steps. Summary of simulated intervention time courses 
with the maximum predicted frequency of remission as a function of repeated 
intervention events simulated in (A) SSRI with behavioral stress management, and 
treatment in the presence of randomly occurring stressful events (30% frequency) without 




































Behavioral Intervention and Stress Management 
 Since pharmacological intervention is typically accompanied by behavioral 
therapy, the experiments described above were repeated, but this time under the 
assumption that the virtual subjects were receiving behavioral therapy that provided them 
with effective strategies for managing stressful events. Optimization of treatment 
schedules and their subsequent simulation was conducted in the absence of stress 
altogether. Results indicated that this simulated behavioral intervention increased the 
efficacy of SSRI treatment significantly. The predicted rate of remission rose almost 
uniformly by up to 10% of treatment attempts across the range of treatment cycles 
(Figure 3; Table 1), far more significantly than the use of combination drug therapy in the 
absence of counseling and lifestyle changes. 
Sensitivity Analysis and Predisposing Factors of Onset  
The results of the sensitivity analysis (Figure 4) showed that starting with health, 
individual deviations in almost all of the neurotransmitters provided no increased risk for 
falling into the depressed steady state beyond random chance. There were, however, three 
significant exceptions. Starting from health, increased levels of NPY served to prevent 
the system from falling into the depression attractor 776 times out of 1000. Low levels of 
NPY had no significant effect. Glutamate, however, had a significant effect at both high 
and low levels. Starting from health with high glutamate, the system fell into depression 
894 times out of 1000. Low levels of glutamate prevented the system from falling into 





Table.  Remission rates of simulated SSRI treatment under various conditions 
	
Number of Treatment Pulses   2 3 4 5 6 7 8 
         
SSRI with stress management 
or no superimposed stress Mean 46.02 61.50 65.37 76.51 77.90 84.35 86.57 
 SD 5.04 4.31 4.64 4.10 3.91 3.41 3.46 
         
SSRI treatment with 30% 
stressful events  Mean 40.05 48.13 58.04 70.81 72.85 78.63 73.08 
 SD 4.82 4.41 5.12 4.27 4.34 4.34 4.79 
         
Combined SSRI/GABA with 
30% stressful events Mean 44.52 51.07 63.47 71.47 76.53 79.45 83.97 
 SD 5.11 4.78 4.92 4.00 4.73 3.83 3.34 
                  
 
Mean and standard deviation (SD) of remission rates obtained in simulations of multiple 
interventions using SSRI alone with an idealized behavioral stress management (BSM) 
therapy (0% stressful events), SSRI treatment without BSM in the presence of external 













Sensitivity Analysis of the Key Factors in Developing Depression. Each node was 
artificially held high, and then low, one at a time. During each orientation, the system 
was allowed to naturally evolve under stress 1000 times. Of those 1000 iterations for 
each orientation, the number of times the system settled in the illness state versus the 














































































































A pathway analysis was conducted to determine the fastest route that the system 
could take to the depressed steady state once introduced to an acute stressor if glutamate 
is held high. This would, in fact, be the fastest route because as the sensitivity analysis 
demonstrated, elevated glutamate provides the environment in which the illness state is 
most often reached when the system is put under stress. Figure 5 shows that the quickest 
route takes a total of six steps to reach depression. In the first step, glutamate and cortisol 
are held high. Attention then drops in step two, followed by an increase in depression in 
step three. GABA is then increased in step four, and serotonin is decreased in step five. 
Finally, due to the decrease in serotonin, physical fatigue decreases in step six. At this 














Path Strip Chart of Fastest Route to Illness State. This analysis determines that, with 
glutamate held high, under the presence of an acute stressor, the system only takes six 
steps to reach the depressed steady state. This breakdown of the temporal progression of 
the shift from health provides insight into which pieces of the system are in motion at 
what times. Beginning with chronically high glutamate levels, the progression involves a 
decrease in attention, an increase in depression, an increase in GABA, a decrease in 






Chapter V: Discussion 
Selective serotonin reuptake inhibitors are often used in clinical practice to treat 
depression. The efficacy of this treatment option varies, but estimates of effectiveness are 
around 50-60%, compared to placebos that work about 40% of the time (Linde, et al., 
2015). The reason why SSRIs do not work 100% of the time to alleviate depression 
remains elusive, but the complicated subjective nature of depression coupled with the 
equally complicated neurophysiological nature of depression likely makes treatment that 
targets a single neurotransmitter too reductive to be an end-all treatment. The intricate 
interworking of depression make this disease, like all mental disorders, difficult to 
pinpoint, and therefore difficult to effectively treat. The model proposed here suggests, in 
a concrete but coarse way, that depression can arise from a web of neuronal activity in 
which more than one piece of the puzzle is off. Serotonin is accurately one of those 
pieces. Modulating serotonin to mimic the introduction of an SSRI treatment, the analysis 
of this model was able to produce similar, but idealized results to SSRI treatment under 
artificial conditions. This suggests two things: the core processes of the model are likely 
correct, and additional granularity is required to further improve accuracy. Future 
iterations of the model will incorporate an even broader, but more comprehensive set of 
systems for developing the full picture of depression. The fact that this is indeed an 
iterative process leaves the door open for further exploration, which is necessary when 
trying to understand something as complex as mental illness.  
Impaired immune system functioning is a common and significant side effect of 
depression (Reiche et al., 2004). A recent study by Yirmiya et al. (2015) proposes a new 




intimately tied to the immune system within the brain. Furthermore, Louveau et al. 
(2015) recently discovered lymphatic vasculature in the central nervous system. This 
anatomical finding will likely have significant implications for the future of 
neuroimmunology. These newfound discoveries stress the importance of developing an 
understanding of psychoneuroimmunology in terms of one interconnected system, and 
not simply in terms of various separate, but peripherally connected, systems. Due to this 
information, the incorporation of the immune system at the molecular level will be the 
most logical next step in the evolution of this model. It is expected that the next iteration 
will provide a more detailed picture of depression and perhaps other mental illnesses and 
neuroimmune disorders. Given the comorbidity rates between depression, anxiety 
disorders such as Generalized Anxiety Disorder and Post-Traumatic Stress Disorder, 
personality disorders, neuroimmune disorders, and physical ailments such as cancer, 
stroke, and cardiovascular disease, it is also expected that future iterations of this model 
will shed some light on the underlying mechanisms connecting any and all of these 
various illnesses. 
 There have been studies modeling the efficacy of various treatments for 
depression, including SSRI use, different forms of psychotherapy, and combinations of 
drug treatment and psychotherapy. Soeteman et al. (2012) used a disease simulation 
model to address the issue of efficacy versus suicide rate of SSRI treatment, cognitive 
behavioral therapy (CBT), and a combination of the two. They found that in the short 
term, a combination treatment worked significantly greater than either form of therapy on 
its own, but when symptoms and suicidality persisted into the long term, CBT was 




constructed by Gruwez et al. (2007) studied the kinetic-pharmacodynamics of the 
antidepressants clomipramine and lithium and how they would be best administered in a 
clinical trial. What these models have in common with the one presented here is the 
ability to see depression and how molecular changes (drug therapy) in combination with 
stress management (psychotherapy) provide the most efficacious treatment outcomes. 
There are, however, significant differences between the established models of depression 
and the one constructed for this study. The first of which is the scope. This model did not 
begin with a theory of depression with which to fit, but instead began as an 
interconnected networking of various neurotransmitters based on current literature. The 
search for possible homeostatic states within working brain chemistry produced a state of 
depression. By first constructing the model and then finding a depressed state, this model 
is better able to see more potential pieces of the network involved in depression than 
current models. These pieces may go unnoticed due to seemingly clinical irrelevance, but 
may, in fact, be key pieces when put into the larger context of the system. Exactly what 
parts these pieces play, and how they interact with stress helps to paint a more vivid 
picture of the underlying mechanisms of depression. For example, this model predicts 
that in this depressed steady state, both cortisol and epinephrine are elevated. These are 
two neurochemicals that aren’t always implicated in typical treatments for depression, but 
according to the wiring of this model based on current literature, they may be somehow 
involved, and therefore potential targets for treatment. Additionally, none of the 
established models sufficiently capture the temporal nature of treatment. This model is 
able to optimize the number and spacing of treatment time steps in order to most 




computer programming and processing, the analyses presented are able to show 
quantitatively the optimal way to treat depression based on the model with SSRIs in the 
presence of stress. Lastly, this model shows the inherent regulatory dynamics of 
depression. Unlike other models and theories, this explains depression as a naturally 
occurring stable regulatory regime within a system that is capable of multi-stability. This 
shows both a new way to conceptualize depression and a new way to address treatment 
plans.  
 To complicate things further, but to add to the homeostatic regime hypothesis of 
the disease, depression is a chronic and recurring illness. Nearly half of all individuals 
who suffer from one episode of major depression will suffer from at least one more later 
in life, and nearly 80% of those who suffer from two episodes will suffer from at least a 
third (Burcusa & Iacono, 2007). These numbers are impressive and demand a more 
comprehensive understanding of depression and what can be done to alleviate it. Stress is 
often one of the triggers for depressive episodes. It is also one of the major causes of 
recurrence (Hammen, 2005). Therefore, in these simulations, 8-treatment serotonin-
boosting and serotonin-and-GABA-combination modules were run, with stress and 
cortisol levels spiking 30% of the time to determine how, based on the model, the ability 
of the depressed steady state to move back toward health would be affected. As one 
might imagine, introducing stress during and after the SSRI treatments, prevented the 
system from returning to health more often than without stress. The success rate of the 
treatment dropped to around 75%, which is closer to real-world statistics. Stress is a 
normal part of everyday life, and the fact that the individual is already suffering from 




handling the stress that they are under.   
 The role that stress plays in depression coupled with the findings from this 
model’s treatment simulations suggest that some form of stress management would be 
beneficial to someone undergoing SSRI treatment for depression. This is consistent with 
the literature that shows different forms of psychotherapy, such as cognitive behavioral 
therapy, in conjunction with SSRIs, produce greater reductions in depression than either 
treatment alone (Chisholm, et al., 2004). Even without pharmacological intervention, 
psychotherapies have been shown to effectively reduce depressive symptoms. Furlong 
and Oei (2002) found that group CBT for depression was effective at reducing scores on 
the Beck Depression Inventory (BDI) by changing automatic thoughts and dysfunctional 
attitudes, thereby adding alternate cognitive pathways to reducing experienced stress. 
Farrer et al. (2011) found that an internet-based CBT program was also significantly 
effective at reducing depression symptoms. While these studies show that CBT can be 
effective at treating depression, March et al. (2004) found that a combination of CBT 
with the SSRI, fluoxetine, significantly reduced scores on the Children’s Depression 
Rating Scale-Revised in 71.0% of subjects, compared to 60.6% of subjects on fluoxetine 
alone, 43.2% of subjects on CBT alone, and 34.8% on placebo. It would seem that 
learning the skills to handle stress is pivotal in maintaining alleviation and remission of 
depression while taking SSRIs. Using this study’s current model and future iterations, 
and the homeostatic drive hypothesis for depression, even more comprehensive treatment 
methods may be uncovered.   
 The sensitivity analysis that was conducted also provided very interesting results, 




depression. This is supported in the literature, as glutamate-blocking compounds have 
been used to treat depression (Niciu, et al., 2014). Müller and Schwarz (2007) actually 
hypothesized that an integrated feedback system between a dysregulated HPA axis, an 
underproduction of serotonin, and an overproduction of glutamate might create a more 
comprehensive picture of depression. The analysis suggests that this line of thinking is 
not only on the right track, but the overproduction of glutamate could potentially lie at the 
source of the depression, providing a key insight into depression onset. This, in itself, 
could have far-reaching implications in terms of the connection between depression and 
healthy lifestyle habits, as the primary source of glutamate in the body comes from 
monosodium glutamate, a common compound found in various types of processed foods. 
 Additionally, the sensitivity analysis found that increased levels of NPY before a 
stressor served a protective role against the onset of depression. This is also supported by 
empirical literature, as Morgan et al. (2002) found that greater levels of NPY release 
during stress are associated with less psychological distress, suggesting that NPY confers 
anxiolytic activity. Similarly, Thorsell (2010) examined the therapeutic implications of 
NPY as a stress mediator. Neuropeptide Y affects the body outside of the brain and 
neurotransmission, however. It has been shown to have direct and significant effects on 
the HPA axis and the immune system. The release of NPY in the brain due to an acute 
stressor has been linked to the release of CRH and the activation of the HPA axis (Hirsch 
& Zukowska, 2012). The discovery of NPY’s potential protective role from this model’s 
depressed steady state suggests that it could be a reasonable target for treatment or 
prevention of depression. 




also of vital importance. The pathway analysis shows not only that the shortest path 
involves six steps, but also exactly what happens in each step. This can have very 
important implications for treatment, because knowing the temporal progression of the 
steady state can provide insight into which molecular targets should be the focus of 
attention, as well as provide further understanding of how depression develops. It could 
also be used to improve current treatment methods by understanding at which relative 
time points various treatments would be most effective. It is important to note, however, 
that the six steps involved in this pathway analysis capture order, but not time steps. 
Further exploration is necessary to determine the length of time between each step. 
 The limitations of this study are exemplified in the coarse-grained development of 
such a complex system. Defining inclusion criteria when creating the network was an 
attempt to limit the amount of noise and erroneous information in the network. However, 
being curated by hand, the network is naturally prone to errors and missing data, despite 
the subsequent analyses supporting a correct construction. Furthermore, liberties were 
taken to determine the direction and polarity of connections. As mentioned, connections 
between any two neurochemicals can be very complex. They can differ based on brain 
region, amount of varying receptors, genetic changes, etc. For the purpose of this study, 
these connections were determined based on an overall, naturally occurring, average way 
that two entities would influence one another, as determined by the literature. As 
technology continues to improve, future studies along these lines will utilize text-mining 
software to determine connections between given entities by compiling data from a vast 
amount of literature to reduce human error, and allow for the inclusion of more 




 Future implications for this research also extend to individualizing treatment. By 
developing an individual illness profile for a patient, an optimized treatment protocol can 
be chosen. Using that same logic, by simulating known treatment protocols, like the SSRI 
simulation, models such as this can potentially discover which illness profiles respond to 
treatment, and which do not, as well as what makes the non-responders unique in their 
presentation. Furthermore, using an existing, validated network, a treatment protocol, or 
other psychological variable with known psychological outcomes or effects, can be 
connected into the model to determine the potential physiological underpinnings. For 
example, by hypothesizing a certain number of incoming and outgoing connections to 
cognitive behavioral therapy, and by constraining those connections to produce a network 
that is less likely to shift from a healthy stable state to a depressed or anxious steady state, 
or, vice versa, more likely to shift from depression or anxiety to health (simulating CBT’s 
antidepressant and anxiolytic effects), a determination could be made on what 
physiological components are directly being influenced by CBT to produce those 
psychological effects. Toole, et al. (2018) did exactly this with psychological well-being, 
examining in a proof-of-concept experiment the physiological components of increasing 
well-being, given its protective role in psychological health. 
 Understanding the true scope of mental illness continues to elude clinicians and 
researchers. What is clear, however, is that mental illness is a very intricate, complicated 
form of disease, affecting or being affected by the interconnected neural network of the 
brain. The concept of the molecular homeostatic drive of the brain and body supporting 
multiple stable states opens the door to new possibilities in understanding the etiologies 




mental illness that needs to be better understood in terms of its intricacies in order to 
illuminate more comprehensive treatment approaches. This project’s model makes a first 
step towards understanding depression, and all mental illness, as one of many prospective 
self-stabilizing states in which the naturally occurring chemistry of the brain can become 
stuck. The discrete logic analysis shows that, in fact, based on current literature-
established neurochemical wiring, the brain is capable of supporting a regime of 
depression. Furthermore, increasing serotonin within this network – mimicking an SSRI 
treatment – can return this dysfunctional steady state back to health. When under random 
instances of stress, however, this return to health is significantly impeded, suggesting that 
for optimal treatment of a depressed neurochemical steady state, some form of behavioral 
intervention involving stress management is necessary. These concepts are reflected in 
clinical cases and real-world depression statistics. By understanding and expounding 
upon this theoretical approach to the underlying mechanisms of depression, and indeed 
all mental illness, it may be possible to soon have a broader, more complete knowledge 
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